Nuvation Bio is a biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases. The company's lead product candidate, NUV-422, is a small molecule inhibitor of CDK2/4/6, which is currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Nuvation Bio is also developing a pipeline of other small molecule inhibitors and biologics for the treatment of cancer and autoimmune diseases. The company was founded in 2018 and is headquartered in San Diego, California.